Cellular and Molecular Mechanisms of Intestinal Fibrosis

다국어 초록 (Multilingual Abstract)

Intestinal fibrosis associated stricture is a common complication of inflammatory bowel disease usually requiring endoscopic or surgical intervention. Effective anti-fibrotic agents aiming to control or reverse intestinal fibrosis are still unavailable. Thus, clarifying the mechanism underpinning intestinal fibrosis is imperative. Fibrosis is characterized by an excessive accumulation of extracellular matrix (ECM) proteins at the injured sites. Multiple cellular types are implicated in fibrosis development. Among these cells, mesenchymal cells are major compartments that are activated and then enhance the production of ECM. Additionally, immune cells contribute to the persistent activation of mesenchymal cells and perpetuation of inflammation. Molecules are messengers of crosstalk between these cellular compartments. Although inflammation is necessary for fibrosis development, purely controlling intestinal inflammation cannot halt the development of fibrosis, suggesting that chronic inflammation is not the unique contributor to fibrogenesis. Several inflammation-independent mechanisms including gut microbiota, creeping fat, ECM interaction, and metabolic reprogramming are involved in the pathogenesis of fibrosis. In the past decades, substantial progress has been made in elucidating the cellular and molecular mechanisms of intestinal fibrosis. Here, we summarized new discoveries and advances of cellular components and major molecular mediators that are associated with intestinal fibrosis, aiming to provide a basis for exploring effective anti-fibrotic therapies in this field.

참고문헌 (Reference)

• 1 Rieder F, "Wound healing and fibrosis in intestinal disease" 56 : 130-139, 2007
• 2 Bauer-Rowe KE, "Where there is fat there is fibrosis : elucidating the mechanisms of creeping fatdriven stricture formation" 233 : S65-, 2021
• 3 Ortiz-Masià D, "WNT2b activates epithelial-mesenchymal transition through FZD4 : relevance in penetrating Crohn´s disease" 14 : 230-239, 2020
• 4 Gieseck RL 3rd, "Type 2 immunity in tissue repair and fibrosis" 18 : 62-76, 2018
• 5 Ha C, "Translocation of viable gut microbiota to mesenteric adipose drives formation of creeping fat in humans" 183 : 666-683, 2020
• 6 Lim WW, "Transgenic interleukin 11 expression causes cross-tissue fibro-inflammation and an inflammatory bowel phenotype in mice" 15 : e0227505-, 2020
• 7 Frangogiannis N, "Transforming growth factor-β in tissue fibrosis" 217 : e20190103-, 2020
• 8 Yang R, "Toll-like receptor 4 contributes to a myofibroblast phenotype in cardiac fibroblasts and is associated with autophagy after myocardial infarction in a mouse model" 279 : 23-31, 2018
• 9 Biancheri P, "The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis" 6 : 13-, 2013
• 10 Derkacz A, "The role of extracellular matrix components in inflammatory bowel diseases" 10 : 1122-, 2021
• 11 Borley NR, "The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease : evidence for a possible causative link" 190 : 196-202, 2000
• 12 Lo BC, "The orphan nuclear receptor RORα and group 3 innate lymphoid cells drive fibrosis in a mouse model of Crohn's disease" 1 : eaaf8864-, 2016
• 13 Klingberg F, "The myofibroblast matrix : implications for tissue repair and fibrosis" 229 : 298-309, 2013
• 14 Bochaton-Piallat ML, "The myofibroblast in wound healing and fibrosis : answered and unanswered questions" 5 (5): 752-, 2016
• 15 Mao R, "The mesenteric fat and intestinal muscle interface : creeping fat influencing stricture formation in Crohn's disease" 25 : 421-426, 2019
• 16 Rieder F, "The gut microbiome in intestinal fibrosis : environmental protector or provocateur?" 5 : 190ps10-, 2013
• 17 Kabata H, "The group 2 innate lymphoid cell(ILC2)regulatory network and its underlying mechanisms" 286 : 37-52, 2018
• 18 Li C, "The fate of myofibroblasts during the development of fibrosis in Crohn's disease" 21 : 326-331, 2020
• 19 Wight TN, "The extracellular matrix: an active or passive player in fibrosis?" 301 : G950-G955, 2011
• 20 Di Gregorio J, "The epithelial-tomesenchymal transition as a possible therapeutic target in fibrotic disorders" 8 : 607483-, 2020
• 21 Scarpa M, "The epithelial danger signal IL-1α is a potent activator of fibroblasts and reactivator of intestinal inflammation" 185 : 1624-1637, 2015
• 22 Cosín-Roger J, "The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD" 9 : 986-998, 2016
• 23 Symowski C, "Th2 cell-derived IL-4/IL-13promote ILC2 accumulation in the lung by ILC2-intrinsic STAT6 signaling in mice" 49 : 1421-1432, 2019
• 24 Patel DD, "Th17 cell pathway in human immunity : lessons from genetics and therapeutic interventions" 43 : 1040-1051, 2015
• 25 Wollheim FA, "Telocytes, communicators in healthy stroma and relation to inflammation and fibrosis" 83 : 615-618, 2016
• 26 Milia AF, "Telocytes in Crohn's disease" 17 : 1525-1536, 2013
• 27 Vannucchi MG, "Telocytes express PDGFRα in the human gastrointestinal tract" 17 : 1099-1108, 2013
• 28 Manetti M, "Telocytes are reduced during fibrotic remodelling of the colonic wall in ulcerative colitis" 19 : 62-73, 2015
• 29 Ibba-Manneschi L, "Telocyte implications in human pathology : an overview" 55 : 62-69, 2016
• 30 Guan Q, "Targeting IL-12/IL-23by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis" 17 : 646-656, 2011
• 31 Yang DH, "TNFSF15 is an independent predictor for the development of Crohn's disease-related complications in Koreans" 8 : 1315-1326, 2014
• 32 Takedatsu H, "TL1A(TNFSF15)regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation" 135 : 552-567, 2008
• 33 Valatas V, "TL1A(TNFSF15)and DR3(TNFRSF25) : a co-stimulatory system of cytokines with diverse functions in gut mucosal immunity" 10 : 583-, 2019
• 34 Migone TS, "TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator" 16 : 479-492, 2002
• 35 Li H, "TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis in mice" 214 : 217-227, 2018
• 36 Macias-Ceja DC, "Succinate receptor mediates intestinal inflammation and fibrosis" 12 : 178-187, 2019
• 37 Allahverdian S, "Smooth muscle cell fate and plasticity in atherosclerosis" 114 : 540-550, 2018
• 38 Muhl L, "Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discrimination" 11 : 3953-, 2020
• 39 Martin JC, "Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy" 178 : 1493-1508, 2019
• 40 Hueber W, "Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease : unexpected results of a randomised, double-blind placebo-controlled trial" 61 : 1693-1700, 2012
• 41 Raghu G, "SAR156597 in idiopathic pulmonary fibrosis : a phase 2 placebo-controlled study(DRI11772)" 52 : 1801130-, 2018
• 42 Li J, "Role of interleukin-17 in pathogenesis of intestinal fibrosis in mice" 65 : 1971-1979, 2020
• 43 Di Gregorio J, "Role of glycogen synthase kinase-3β and PPAR-γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis" 12 : e0171093-, 2017
• 44 Lovisa S, "Role of epithelial-to-mesenchymal transition in inflammatory bowel disease" 13 : 659-668, 2019
• 45 D'Alessio S, "Revisiting fibrosis in inflammatory bowel disease : the gut thickens" 19 : 169-184, 2022
• 46 Guan Q, "Reversing ongoing chronic intestinal inflammation and fibrosis by sustained block of IL-12 and IL-23 using a vaccine in mice" 24 : 1941-1952, 2018
• 47 Xiong S, "Reverse translation approach generates a signature of penetrating fibrosis in Crohn's disease that is associated with anti-TNF response" 71 : 1289-1301, 2022
• 48 Latella G, "Results of the 4th scientific workshop of the ECCO(I) : pathophysiology of intestinal fibrosis in IBD" 8 : 1147-1165, 2014
• 49 Brockmann L, "Regulation of TH17 cells and associated cytokines in wound healing, tissue regeneration, and carcinogenesis" 18 : 1033-, 2017
• 50 Aran D, "Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage" 20 : 163-172, 2019
• 51 Leeb SN, "Reduced migration of fibroblasts in inflammatory bowel disease : role of inflammatory mediators and focal adhesion kinase" 125 : 1341-1354, 2003
• 52 Gibbs BF, "Purified human peripheral blood basophils release interleukin-13 and preformed interleukin-4 following immunological activation" 26 : 2493-2498, 1996
• 53 Drygiannakis I, "Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts : implication in intestinal fibrosis" 7 : 286-300, 2013
• 54 Lu W, "Platelet-derived growth factor C signaling is a potential therapeutic target for radiation proctopathy" 13 : eabc2344-, 2021
• 55 Maher TM, "Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis" 57 : 1902442-, 2021
• 56 Bhattacharyya S, "Pharmacological inhibition of Toll-like receptor-4 signaling by TAK242 prevents and induces regression of experimental organ fibrosis" 9 : 2434-, 2018
• 57 Chang JT, "Pathophysiology of inflammatory bowel diseases" 383 : 2652-2664, 2020
• 58 Zidar N, "Pathology of fibrosis in Crohn's disease-contribution to understanding its pathogenesis" 7 : 167-, 2020
• 59 Zorzi F, "Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease" 129 : 1107-1113, 2015
• 60 Li J, "Pathogenesis of fibrostenosing Crohn's disease" 209 : 39-54, 2019
• 61 Wohlfahrt T, "PU. 1 controls fibroblast polarization and tissue fibrosis" 566 : 344-349, 2019
• 62 LeBleu VS, "Origin and function of myofibroblasts in kidney fibrosis" 19 : 1047-1053, 2013
• 63 Weiskirchen R, "Organ and tissue fibrosis : molecular signals, cellular mechanisms and translational implications" 65 : 2-15, 2019
• 64 West NR, "Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease" 23 : 579-589, 2017
• 65 Wang J, "Novel mechanisms and clinical trial endpoints in intestinal fibrosis" 302 : 211-227, 2021
• 66 Li C, "Noncanonical STAT3 activation regulates excess TGF-β1 and collagen I expression in muscle of stricturing Crohn's disease" 194 : 3422-3431, 2015
• 67 Baumgart DC, "Newer biologic and small-molecule therapies for inflammatory bowel disease" 385 : 1302-1315, 2021
• 68 Rock JR, "Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition" 108 : E1475-E1483, 2011
• 69 Dohi T, "Mice deficient in Th1-and Th2-type cytokines develop distinct forms of hapten-induced colitis" 119 : 724-733, 2000
• 70 Bos S, "Metabolic modulation during intestinal fibrosis" 21 : 319-325, 2020
• 71 Rieder F, "Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases" 152 : 340-350, 2017
• 72 Li C, "Mechanisms that mediate the development of fibrosis in patients with Crohn's disease" 20 : 1250-1258, 2014
• 73 Wynn TA, "Mechanisms of fibrosis : therapeutic translation for fibrotic disease" 18 : 1028-1040, 2012
• 74 D'Urso M, "Mechanical and physical regulation of fibroblast-myofibroblast transition : from cellular mechanoresponse to tissue pathology" 8 : 609653-, 2020
• 75 Frid MG, "Mature vascular endothelium can give rise to smooth muscle cells via endothelialmesenchymal transdifferentiation : in vitro analysis" 90 : 1189-1196, 2002
• 76 Krystel-Whittemore M, "Mast cell : a multi-functional master cell" 6 : 620-, 2016
• 77 Wynn TA, "Macrophages in tissue repair, regeneration, and fibrosis" 44 : 450-462, 2016
• 78 Honzawa Y, "Involvement of interleukin-17A-induced expression of heat shock protein 47in intestinal fibrosis in Crohn's disease" 63 : 1902-1912, 2014
• 79 Mifflin RC, "Intestinal myofibroblasts : targets for stem cell therapy" 300 : G684-G696, 2011
• 80 Rieder F, "Intestinal fibrosis in IBD : a dynamic, multifactorial process" 6 : 228-235, 2009
• 81 Lenti MV, "Intestinal fibrosis" 65 : 100-109, 2019
• 82 Franzè E, "Interleukin-34sustains inflammatory pathways in the gut" 129 : 271-280, 2015
• 83 Baghdadi M, "Interleukin-34, a comprehensive review" 104 : 931-951, 2018
• 84 Franzè E, "Interleukin-34 stimulates gut fibroblasts to produce collagen synthesis" 14 : 1436-1445, 2020
• 85 Hwang SJ, "Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis" 14 : R14-, 2012
• 86 Kobori A, "Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis" 45 : 999-1007, 2010
• 87 Zheng Y, "Interleukin-22mediates early host defense against attaching and effacing bacterial pathogens" 14 : 282-289, 2008
• 88 Andoh A, "Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts" 129 : 969-984, 2005
• 89 Okuno T, "Interleukin-1beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts" 37 : 317-324, 2002
• 90 Ramani K, "Interleukin-17 : friend or foe in organ fibrosis" 120 : 282-288, 2019
• 91 Ng B, "Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis" 11 : eaaw1237-, 2019
• 92 Mantovani A, "Interleukin-1 and related cytokines in the regulation of inflammation and immunity" 50 : 778-795, 2019
• 93 Andoh A, "Interleukin(IL)-4 and IL-17 synergistically stimulate IL-6 secretion in human colonic myofibroblasts" 10 : 631-634, 2002
• 94 Liang SC, "Interleukin(IL)-22and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides" 203 : 2271-2279, 2006
• 95 Takahashi K, "Interleukin(IL)-1βis a strong inducer of IL-36γ expression in human colonic myofibroblasts" 10 : e0138423-, 2015
• 96 Zwicker S, "Interleukin 34: a new modulator of human and experimental inflammatory bowel disease" 129 : 281-290, 2015
• 97 Eberl G, "Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology" 348 : aaa6566-, 2015
• 98 Klose CS, "Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis" 17 : 765-774, 2016
• 99 Zenewicz LA, "Innate and adaptive interleukin-22protects mice from inflammatory bowel disease" 29 : 947-957, 2008
• 100 Ulloa L, "Inhibition of transforming growth factor-beta/SMAD signalling by the interferongamma/STAT pathway" 397 : 710-713, 1999
• 101 Shih DQ, "Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis" 7 : 1492-1503, 2014
• 102 Scheibe K, "Inhibiting interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation" 156 : 1082-1097, 2019
• 103 Yagi Y, "Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts" 42 : 746-753, 2007
• 104 Rieder F, "Inflammation-induced endothelial-to-mesenchymal transition : a novel mechanism of intestinal fibrosis" 179 : 2660-2673, 2011
• 105 Jacob N, "Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome" 11 : 1466-1476, 2018
• 106 Kuroda N, "Infiltrating CCR2+monocytes and their progenies, fibrocytes, contribute to colon fibrosis by inhibiting collagen degradation through the production of TIMP-1" 9 : 8568-, 2019
• 107 Mathur R, "Induction of autophagy in Cx3cr1+ mononuclear cells limits IL-23/IL-22 axismediated intestinal fibrosis" 12 : 612-623, 2019
• 108 Fichtner-Feigl S, "Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2, 4, 6-trinitrobenzene sulfonic acid colitis" 178 : 5859-5870, 2007
• 109 Nishida A, "Increased expression of interleukin-36, a member of the interleukin-1 cytokine family, in inflammatory bowel disease" 22 : 303-314, 2016
• 110 Li C, "Increased activation of latent TGF-β1 by αVβ3 in human Crohn's disease and fibrosis in TNBS colitis can be prevented by cilengitide" 19 : 2829-2839, 2013
• 111 Coffey CJ, "Inclusion of the mesentery in ileocolic resection for Crohn's disease is associated with reduced surgical recurrence" 12 : 1139-1150, 2018
• 112 Flier SN, "Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis" 285 : 20202-20212, 2010
• 113 Walana W, "IL-8 antagonist, CXCL8(3-72)K11R/G31P coupled with probiotic exhibit variably enhanced therapeutic potential in ameliorating ulcerative colitis" 103 : 253-261, 2018
• 114 Pelly VS, "IL-4-producing ILC2s are required for the differentiation of TH2 cells following Heligmosomoides polygyrus infection" 9 : 1407-1417, 2016
• 115 Scheibe K, "IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo" 66 : 823-838, 2017
• 116 Elias M, "IL-36 in chronic inflammation and fibrosis: bridging the gap?" 131 : e144336-, 2021
• 117 Preisser L, "IL-34and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells" 60 : 1879-1890, 2014
• 118 Baek JH, "IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease" 125 : 3198-3214, 2015
• 119 Kotsiou OS, "IL-33/ST2axis in organ fibrosis" 9 : 2432-, 2018
• 120 Schmitz J, "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines" 23 : 479-490, 2005
• 121 Lopetuso LR, "IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair" 115 : E9362-E9370, 2018
• 122 Borowczyk J, "IL-25(IL-17E)in epithelial immunology and pathophysiology" 148 : 40-52, 2021
• 123 McGee HM, "IL-22 promotes fibroblast-mediated wound repair in the skin" 133 : 1321-1329, 2013
• 124 Zhang HJ, "IL-17A promotes initiation and development of intestinal fibrosis through EMT" 63 : 2898-2909, 2018
• 125 Paul J, "IL-17-driven intestinal fibrosis is inhibited by Itch-mediated ubiquitination of HIC-5" 11 : 427-436, 2018
• 126 Fichtner-Feigl S, "IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis" 135 : 2003-2013, 2008
• 127 Schafer S, "IL-11 is a crucial determinant of cardiovascular fibrosis" 552 : 110-115, 2017
• 128 Dharmasiri S, "Human intestinal macrophages are involved in the pathology of both ulcerative colitis and Crohn disease" 27 : 1641-1652, 2021
• 129 Ng EK, "Human intestinal epithelial and smooth muscle cells are potent producers of IL-6" 12 : 3-8, 2003
• 130 Darfeuille-Michaud A, "High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease" 127 : 412-421, 2004
• 131 Cook SA, "Hiding in plain sight : interleukin-11emerges as a master regulator of fibrosis, tissue integrity, and stromal inflammation" 71 : 263-276, 2020
• 132 Theiss AL, "Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation" 129 : 204-219, 2005
• 133 Messing M, "Group 2 innate lymphoid cells : central players in a recurring theme of repair and regeneration" 21 : 1350-, 2020
• 134 Wang AJ, "Genetic deletion of IL-25(IL-17E)confers resistance to dextran sulfate sodium-induced colitis in mice" 4 : 72-, 2014
• 135 Imai J, "Flagellin-mediated activation of IL-33-ST2 signaling by a pathobiont promotes intestinal fibrosis" 12 : 632-643, 2019
• 136 Wynn TA, "Fibrotic disease and the T(H)1/T(H)2 paradigm" 4 : 583-594, 2004
• 137 de Bruyn JR, "Fibrostenotic phenotype of myofibroblasts in Crohn’s disease is dependent on tissue stiffness and reversed by LOX inhibition" 12 : 849-859, 2018
• 138 Barron L, "Fibrosis is regulated by Th2 and Th17responses and by dynamic interactions between fibroblasts and macrophages" 300 : G723-G728, 2011
• 139 Gordon IO, "Fibrosis in ulcerative colitis : mechanisms, features, and consequences of a neglected problem" 20 : 2198-2206, 2014
• 140 Henderson NC, "Fibrosis : from mechanisms to medicines" 587 : 555-566, 2020
• 141 Sazuka S, "Fibrocytes are involved in inflammation as well as fibrosis in the pathogenesis of Crohn's disease" 59 : 760-768, 2014
• 142 Davidson S, "Fibroblasts as immune regulators in infection, inflammation and cancer" 21 : 704-717, 2021
• 143 Baum J, "Fibroblasts and myofibroblasts : what are we talking about?" 57 : 376-379, 2011
• 144 Sheehan AL, "Fat-wrapping in Crohn's disease : pathological basis and relevance to surgical practice" 79 : 955-958, 1992
• 145 Herrera J, "Extracellular matrix as a driver of progressive fibrosis" 128 : 45-53, 2018
• 146 Iwano M, "Evidence that fibroblasts derive from epithelium during tissue fibrosis" 110 : 341-350, 2002
• 147 Bataille F, "Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease" 14 : 1514-1527, 2008
• 148 Kalluri R, "Epithelial-mesenchymal transition and its implications for fibrosis" 112 : 1776-1784, 2003
• 149 Masterson JC, "Eosinophils and IL-33 perpetuate chronic inflammation and fibrosis in a pediatric population with stricturing Crohn's ileitis" 21 : 2429-2440, 2015
• 150 Takemura N, "Eosinophil depletion suppresses radiation-induced small intestinal fibrosis" 10 : eaan0333-, 2018
• 151 Zhang Y, "Endothelial to mesenchymal transition contributes to arsenic-trioxide-induced cardiac fibrosis" 6 : 33787-, 2016
• 152 Flynn RS, "Endogenous IGF-I and alphaVbeta3 integrin ligands regulate increased smooth muscle hyperplasia in stricturing Crohn's disease" 138 : 285-293, 2010
• 153 Lopetuso LR, "Emerging role of the interleukin(IL)-33/ST2 axis in gut mucosal wound healing and fibrosis" 5 : 18-, 2012
• 154 Wenxiu J, "Effect and mechanism of TL1A expression on epithelial-mesenchymal transition during chronic colitis-related intestinal fibrosis" 2021 : 5927064-, 2021
• 155 Santamaria PG, "EMT : present and future in clinical oncology" 11 : 718-738, 2017
• 156 Driskell RR, "Distinct fibroblast lineages determine dermal architecture in skin development and repair" 504 : 277-281, 2013
• 157 Forkel M, "Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established Crohn’s disease and ulcerative colitis" 13 : 67-78, 2019
• 158 Jacob N, "Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo" 10 : 18189-, 2020
• 159 Klose C, "Differentiation of type 1ILCs from a common progenitor to all helper-like innate lymphoid cell lineages" 157 : 340-356, 2014
• 160 Rogler G, "Differential activation of cytokine secretion in primary human colonic fibroblast/myofibroblast cultures" 36 : 389-398, 2001
• 161 Francoeur C, "Degeneration of the pericryptal myofibroblast sheath by proinflammatory cytokines in inflammatory bowel diseases" 136 : 268-277, 2009
• 162 Friedrich M, "Cytokine networks in the pathophysiology of inflammatory bowel disease" 50 : 992-1006, 2019
• 163 Gladiator A, "Cutting edge : IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection" 190 : 521-525, 2013
• 164 Soroosh A, "Crohn's disease fibroblasts overproduce the novel protein KIAA1199 to create proinflammatory hyaluronan fragments" 2 : 358-368, 2016
• 165 Rieder F, "Crohn's disease complicated by strictures : a systematic review" 62 : 1072-1084, 2013
• 166 Mao R, "Creeping-fat derived free fatty acids induce hyperplasia of intestinal muscularis propria muscle cells : a novel link between fat and intestinal stricture formation in Crohn's disease" 154 : S-131-, 2018
• 167 Monteleone G, "Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21" 55 : 1774-1780, 2006
• 168 Severi C, "Contribution of intestinal smooth muscle to Crohn's disease fibrogenesis" 58 : 2457-, 2014
• 169 Liu Q, "Constrictive and hypertrophic strictures in ileal Crohn's disease" 20 : e1292-e1304, 2022
• 170 Shih DQ, "Constitutive TL1A(TNFSF15)expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis" 6 : e16090-, 2011
• 171 Barrett R, "Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis" 180 : 636-649, 2012
• 172 Sahebally SM, "Circulating fibrocytes and Crohn's disease" 100 : 1549-1556, 2013
• 173 Grieb G, "Circulating fibrocytes : biology and mechanisms in wound healing and scar formation" 291 : 1-19, 2011
• 174 Lawrance IC, "Cellular and molecular mediators of intestinal fibrosis" 11 : 1491-1503, 2017
• 175 Speca S, "Cellular and molecular mechanisms of intestinal fibrosis" 18 : 3635-3661, 2012
• 176 Wynn TA, "Cellular and molecular mechanisms of fibrosis" 214 : 199-210, 2008
• 177 Li GQ, "Celastrol inhibits interleukin-17A-stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF-κBmediated matrix metalloproteinase-9 expression" 14 : 422-431, 2012
• 178 Franzè E, "Cadherin-11 is a regulator of intestinal fibrosis" 14 : 406-417, 2020
• 179 Salvador P, "CD16+ macrophages mediate fibrosis in inflammatory bowel disease" 12 : 589-599, 2018
• 180 Kobayashi M, "Bioengineering functional smooth muscle with spontaneous rhythmic contraction in vitro" 8 : 13544-, 2018
• 181 Galdiero MR, "Bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer" 4 : 103-, 2017
• 182 Gumaste V, "Benign and malignant colorectal strictures in ulcerative colitis" 33 : 938-941, 1992
• 183 Louis E, "Behaviour of Crohn's disease according to the Vienna classification : changing pattern over the course of the disease" 49 : 777-782, 2001
• 184 Ueno A, "Association of circulating fibrocytes with fibrostenotic small bowel Crohn's disease" 28 : 246-258, 2022
• 185 Hassan-Zahraee M, "Antitumor necrosis factor-like ligand 1A therapy targets tissue inflammation and fibrosis pathways and reduces gut pathobionts in ulcerative colitis" 28 : 434-446, 2022
• 186 Rieder F, "An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease" 48 : 347-357, 2018
• 187 Clarke AW, "An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease" 10 : 664-677, 2018
• 188 Morimoto Y, "Amphiregulinproducing pathogenic memory T helper 2 cells instruct eosinophils to secrete osteopontin and facilitate airway fibrosis" 49 : 134-150, 2018
• 189 Gordon S, "Alternative activation of macrophages : mechanism and functions" 32 : 593-604, 2010
• 190 Lawrance IC, "Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease" 7 : 226-236, 2001
• 191 Sugiura H, "Activation of Tolllike receptor 3 augments myofibroblast differentiation" 40 : 654-662, 2009
• 192 Mao R, "Activated intestinal muscle cells promote preadipocyte migration : a novel mechanism for creeping fat formation in Crohn's disease" 71 : 55-67, 2022
• 193 Targan SR, "A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease" 111 : 1599-1607, 2016
• 194 Allanore Y, "A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-ofconcept study of romilkimab(SAR156597)in early diffuse cutaneous systemic sclerosis" 79 : 1600-1607, 2020
• 195 Mao R, "A positive feedback loop between creeping fat and intestinal stricture formation in Crohn's disease : the role of creeping fat-derived free fatty acids, extracellular matrix, and integrin" 158 : S-188-S-189, 2020
• 196 Raghu G, "A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis" 350 : 125-133, 2004
• 197 Nayar S, "A myeloid-stromal niche and gp130 rescue in NOD2-driven Crohn's disease" 593 : 275-281, 2021
• 198 Bauer-Rowe KE, "A Surgical model for investigating the role of creeping fat in intestinal fibrosis" 231 : S50-S51, 2020